Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Ovarian Neoplasms 35Breast Neoplasms 32Lung Neoplasms 28Uterine Cervical Neoplasms 18Triple Negative Breast Neoplasms 15Fallopian Tube Neoplasms 15Carcinoma, Ovarian Epithelial 15Small Cell Lung Carcinoma 13Squamous Cell Carcinoma of Head and Neck 10Neuroblastoma 10Esophageal Neoplasms 10Esophageal Squamous Cell Carcinoma 8Central Nervous System Neoplasms 8Recurrence 7Head and Neck Neoplasms 6Endometrial Neoplasms 6Retinoblastoma 5Neoplasm Metastasis 5Brain Neoplasms 5Adenocarcinoma of Lung 5Neoplasms 4Melanoma 4Carcinoma, Squamous Cell 4Testicular Neoplasms 3Oligodendroglioma 3Medulloblastoma 3Lymphoma, Large B-Cell, Diffuse 3Hodgkin Disease 3Glioblastoma 3

Interventions

anlotinib 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × SCLC × Carboplatin × Clear all
NCT04684017 2020-12-24

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer

Shanghai Chest Hospital

Phase 2 Unknown
29 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡